First Ascent Biomedical announced the completion of a new lab in Erie ahead of schedule.
Public source
Publisher name
Public post
What a great trip to Erie last week. The new lab is spectacular and ahead of schedule. We can’t wait as we bring our technology to those patients battling cancer.
Company
First Ascent Biomedical
Precision Medicine Platform: Providing doctors with data to design treatments as unique as you are.
- Industry
- Biotechnology Research
- Location
- Miami, US
- Company size
- 11–50 employees
About First Ascent Biomedical
For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work. To Learn More- Contact us at: info@firstascentbio.com Or go to: www.FirstAscentBio.com
See moreLatest activity
Latest activity from First Ascent Biomedical
11 signals
Products & Services
First Ascent Biomedical launched xDrive, a clinical trial platform that delivers live-cell and genomic insights for drug development support and clinical decision-making.
Presence & Recognition
First Ascent Biomedical announced that Gannon University is participating in PrecisionFunctionalOncology and FunctionalPrecisionMedicine.
Products & Services
First Ascent Biomedical aims to deliver a ranked report in 10 days for xDrive, which is now commercially available under CLIA-CAP standards.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Frederick National Laboratory for Cancer Research
Frederick National Laboratory for Cancer Research scientists developed and released the first publicly available tissue microarray panel for the NCI Patient-Derived Models Repository.
Products & Services
Oncofuse
Oncofuse built and fully built the foundation for its next big chapter.
Products & Services
TubeWriter
TubeWriter launched the TubeWriter 400, a permanent UV-cured ink marking system capable of marking up to 50 tubes in 90 seconds.
Products & Services
Integrated DNA Technologies
Integrated DNA Technologies expanded its synthesis capabilities to help researchers access diversity, quality, and scale needed for the next generation of cancer research.
Products & Services
Empyrean Medical Systems, Inc.